Literature DB >> 30882868

Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.

Omid Beiki1,2,3, Paolo Frumento4, Matteo Bottai4, Ali Manouchehrinia1, Jan Hillert1.   

Abstract

Importance: Clinicians' experience and findings from recent natural history studies suggest that multiple sclerosis (MS) may now be running a more slowly progressing course than before. Objective: To investigate whether the risk of reaching MS disability milestones has changed over the last decade in Sweden. Design, Setting, and Participants: A nationwide population-based retrospective cohort study. By April 2017, 12 512 patients with available information on demographics, MS phenotype, and date of MS onset and diagnosis were registered in the Swedish MS Registry of which 7331 patients with at least 2 recorded Expanded Disability Status Scale scores (EDSS) and diagnosed between January 1995 and December 2010 were included. No further exclusion criteria were applied. Patients were followed up until December 2016 with a median duration follow-up of 8.5 (interquartile range, 4.7-13.8) years. Statistical analysis began in April 2017. Main Outcomes and Measures: Patients were followed up from MS onset date to the date of sustained EDSS 3.0, 4.0, and 6.0. To handle interval-censored observations, a Weibull model was fit, and the change in the risk of EDSS 3.0, 4.0, and 6.0 over calendar years was estimated and hazard ratios (HRs) with corresponding CIs were calculated.
Results: Of 7331 patients, 5196 (70.9%) were women, and the mean (SD) age at diagnosis was 38.3 (11.7) years. Adjusting for sex, number of clinic visits, diagnostic delay, and onset age, a 3% decrease per calendar year of diagnosis for the risk of sustained EDSS 3.0 (HR, 0.97; 95% CI, 0.96-0.97), a 6% decrease for the risk of EDSS 4.0 (HR, 0.94; 95% CI, 0.93-0.95), and a 7% decrease for the risk of EDSS 6.0 (HR, 0.93; 95% CI, 0.91-0.94) among patients with relapsing-onset MS was found. The trends were not significant for patients with progressive-onset MS (EDSS 3.0: HR, 1.01; 95% CI, 0.98-1.03; EDSS 4.0: HR, 1.00; 95% CI, 0.98-1.02; EDSS 6.0: HR, 1.00; 95% CI, 0.98-1.02). Conclusions and Relevance: Risk of reaching major disability milestones has significantly decreased over the last decade in patients with relapsing-onset MS in Sweden. Several factors could potentially be responsible for this observation. However, given that no change was seen in disability accrual of patients with progressive-onset MS and the absence of efficacious treatment option in this group, increased use of more efficacious disease-modifying treatments could be a possible driver of this change.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30882868      PMCID: PMC6563565          DOI: 10.1001/jamaneurol.2019.0330

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  36 in total

1.  Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009).

Authors:  Afsaneh Shirani; Yinshan Zhao; Elaine Kingwell; Peter Rieckmann; Helen Tremlett
Journal:  Mult Scler       Date:  2011-09-27       Impact factor: 6.312

2.  Disease progression in multiple sclerosis: combining physicians' and patients' perspectives?

Authors:  J J Kragt; J M Nielsen; F A H van der Linden; C H Polman; B M J Uitdehaag
Journal:  Mult Scler       Date:  2010-10-26       Impact factor: 6.312

3.  EDSS improvement: recovery of function or noise?

Authors:  Daniel Ontaneda; Jeffrey A Cohen
Journal:  Mult Scler       Date:  2012-11       Impact factor: 6.312

4.  Characterization of annual disease progression of multiple sclerosis patients: A population-based study.

Authors:  Jonatan Freilich; Ali Manouchehrinia; Mark Trusheim; Lynn G Baird; Sophie Desbiens; Ernst Berndt; Jan Hillert
Journal:  Mult Scler       Date:  2017-05-08       Impact factor: 6.312

5.  Increasing age at disability milestones among MS patients in the MSBase Registry.

Authors:  Ilya Kister; Eric Chamot; Gary Cutter; Tamar E Bacon; Vilija G Jokubaitis; Stella E Hughes; Orla M Gray; Maria Trojano; Guillermo Izquierdo; Francois Grand'Maison; Pierre Duquette; Alessandra Lugaresi; Pierre Grammond; Cavit Boz; Raymond Hupperts; Thor Petersen; Giorgio Giuliani; Celia Oreja-Guevara; Gerardo Iuliano; Jeannette Lechner-Scott; Roberto Bergamaschi; Maria Edite Rio; Freek Verheul; Marcela Fiol; Vincent Van Pesch; Mark Slee; Helmut Butzkueven; Joseph Herbert
Journal:  J Neurol Sci       Date:  2012-04-14       Impact factor: 3.181

6.  Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012.

Authors:  Sarah Burkill; Scott Montgomery; MohammadHossein Hajiebrahimi; Jan Hillert; Tomas Olsson; Shahram Bahmanyar
Journal:  Neurology       Date:  2017-07-07       Impact factor: 9.910

7.  Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation.

Authors:  P J Veugelers; J D Fisk; M G Brown; K Stadnyk; I S Sketris; T J Murray; V Bhan
Journal:  Mult Scler       Date:  2009-10-30       Impact factor: 6.312

Review 8.  Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression.

Authors:  Simon M Steinvorth; Christian Röver; Simon Schneider; Richard Nicholas; Sebastian Straube; Tim Friede
Journal:  Mult Scler       Date:  2013-03-07       Impact factor: 6.312

9.  Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis.

Authors:  R Zivadinov; M Zorzon; B Weinstock-Guttman; M Serafin; A Bosco; A Bratina; C Maggiore; A Grop; M A Tommasi; B Srinivasaraghavan; M Ramanathan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-01-23       Impact factor: 10.154

10.  Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression.

Authors:  Christian Röver; Richard Nicholas; Sebastian Straube; Tim Friede
Journal:  PLoS One       Date:  2015-09-01       Impact factor: 3.240

View more
  10 in total

1.  Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.

Authors:  Natalie A Schwehr; Karen M Kuntz; Mary Butler; Eva A Enns; Nathan D Shippee; Elaine Kingwell; Helen Tremlett; Adam F Carpenter
Journal:  Mult Scler       Date:  2019-07-29       Impact factor: 6.312

Review 2.  [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].

Authors:  Heinz Wiendl; Ralf Gold; Thomas Berger; Tobias Derfuss; Ralf Linker; Mathias Mäurer; Martin Stangel; Orhan Aktas; Karl Baum; Martin Berghoff; Stefan Bittner; Andrew Chan; Adam Czaplinski; Florian Deisenhammer; Franziska Di Pauli; Renaud Du Pasquier; Christian Enzinger; Elisabeth Fertl; Achim Gass; Klaus Gehring; Claudio Gobbi; Norbert Goebels; Michael Guger; Aiden Haghikia; Hans-Peter Hartung; Fedor Heidenreich; Olaf Hoffmann; Zoë R Hunter; Boris Kallmann; Christoph Kleinschnitz; Luisa Klotz; Verena Leussink; Fritz Leutmezer; Volker Limmroth; Jan D Lünemann; Andreas Lutterotti; Sven G Meuth; Uta Meyding-Lamadé; Michael Platten; Peter Rieckmann; Stephan Schmidt; Hayrettin Tumani; Martin S Weber; Frank Weber; Uwe K Zettl; Tjalf Ziemssen; Frauke Zipp
Journal:  Nervenarzt       Date:  2021-07-23       Impact factor: 1.214

3.  Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60.

Authors:  Le H Hua; Carrie M Hersh; Fan Tian; Ellen M Mowry; Kathryn C Fitzgerald
Journal:  Mult Scler Relat Disord       Date:  2020-11-23       Impact factor: 4.339

Review 4.  Diagnosis and Management of Progressive Multiple Sclerosis.

Authors:  Gabrielle Macaron; Daniel Ontaneda
Journal:  Biomedicines       Date:  2019-07-29

Review 5.  Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives.

Authors:  Elisabeth G Celius; Heidi Thompson; Maija Pontaga; Dawn Langdon; Alice Laroni; Stanca Potra; Trishna Bharadia; David Yeandle; Jane Shanahan; Pieter van Galen; Nektaria Alexandri; Jürg Kesselring
Journal:  Patient Prefer Adherence       Date:  2021-01-08       Impact factor: 2.711

6.  Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis.

Authors:  Dalia Rotstein; Jacqueline M Solomon; Maria Pia Sormani; Xavier Montalban; Xiang Y Ye; Dina Dababneh; Alexandra Muccilli; Georges Saab; Prakesh Shah
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-10-12

7.  Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry.

Authors:  Cecilia Smith Simonsen; Heidi Øyen Flemmen; Line Broch; Cathrine Brunborg; Pål Berg-Hansen; Stine Marit Moen; Elisabeth Gulowsen Celius
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

Review 8.  Artificial intelligence extension of the OSCAR-IB criteria.

Authors:  Axel Petzold; Philipp Albrecht; Laura Balcer; Erik Bekkers; Alexander U Brandt; Peter A Calabresi; Orla Galvin Deborah; Jennifer S Graves; Ari Green; Pearse A Keane; Jenny A Nij Bijvank; Josemir W Sander; Friedemann Paul; Shiv Saidha; Pablo Villoslada; Siegfried K Wagner; E Ann Yeh
Journal:  Ann Clin Transl Neurol       Date:  2021-05-19       Impact factor: 4.511

9.  Internuclear Ophthalmoplegia as the First Manifestation of Pediatric-Onset Multiple Sclerosis and Concurrent Lyme Disease.

Authors:  Jonathan Chao; Sandal Saleem; Hassan N Tausif; Kelly Levasseur; Lori A Stec
Journal:  Am J Case Rep       Date:  2020-10-07

10.  The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression.

Authors:  Cecilia Smith Simonsen; Heidi Øyen Flemmen; Line Broch; Cathrine Brunborg; Pål Berg-Hansen; Stine Marit Moen; Elisabeth Gulowsen Celius
Journal:  J Neurol       Date:  2020-10-22       Impact factor: 4.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.